Verana Health

Investment and strategic decisions are led by CEO Sujay Jadhav, who joined in 2021. The board includes representatives from major investors such as Kleiner Perkins, GV, Novo Holdings, and Deerfield Management.

Executive Chairman David W. Parke II, former CEO of the American Academy of Ophthalmology, provides oversight.

The firm does not disclose an internal investment committee or CIO role.

Verana Health obtains data through exclusive partnerships with medical specialty societies, including the American Academy of Ophthalmology and the American Urological Association.

It manages the IRIS Registry (ophthalmology) and AQUA Registry (urology), collecting de-identified electronic health record data from over 20,000 clinicians.

This exclusive access means competitors cannot license the same datasets.

Verana Health is a venture-backed digital health company, not a family office.

Its investors include institutional venture capital firms (Kleiner Perkins, GV, Novo Holdings) and corporate venture arms (Johnson & Johnson Innovation, Merck).

The firm does not have a disclosed single-family-office backer.

The firm’s core therapeutic areas are ophthalmology and urology, via its exclusive society partnerships.

It has since expanded into neurology and oncology, the latter led by Chief Medical Officer C.K. Wang following a merger with COTA.

Oncology datasets now include bladder, ovarian, and prostate cancer.

Yes. Verana Health serves life sciences companies with real-world evidence studies, clinical trial site selection, patient recruitment, and commercialization analytics.

The firm states that the top four of five largest pharmaceutical companies are customers (per firm website, 2025).

It also offers MIPS quality reporting for clinicians and registry management for medical societies.

Verana Health competes with other real-world data and evidence firms such as Flatiron Health (oncology-focused, now part of Roche), IQVIA, and COTA (which it merged with).

Its exclusive society partnerships create a moat in ophthalmology and urology that competitors cannot easily replicate.

The firm differentiates through clinician-directed data curation and AI-driven data integrity loops.

Verana Health applies AI and machine learning to structure and enrich clinical data from electronic health records.

Its platform, VeraQ, uses AI for natural language processing of unstructured clinical notes and to power a data integrity feedback loop.

The firm has also introduced AI agents for tasks such as MIPS submission compliance and site selection for trials.

Verana Health is headquartered in San Francisco, CA, with additional offices in New York, NY and Knoxville, TN.

Its data network covers clinicians across the United States, with no disclosed international operations.

Patients in the network are de-identified and sourced from U.S. healthcare providers.